\-\ Texto\\:\\ \ \(0\)\
\-\ \\+3\\ hyperreflexia\\ of\\ the\\ lower\\ extremities\ \(1\)\
\-\ patient\\ is\\ currently\\ being\\ treated\\ conservatively\\ with\\ pain\\ meds\\ as\\ needed\\.\ \(0\)\
\-\ mri\\ of\\ the\\ spine\\ demonstrates\\ proliferation\\ of\\ the\\ dorsal\\ epidural\\ fat\\ associated\\ with\\ complete\\ effacement\\ of\\ the\\ dorsal\\ sub\\ arachnoid\\ space\\ from\\ the\\ t3\\ \\-\\ t9\\ levels\\ which\\ results\\ in\\ moderate\\ central\\ canal\\ stenosis\\ mild\\ ventral\\ cord\\ flattening\\ at\\ the\\ t6\\-7\\ level\\.\\ \\ there\\ is\\ also\\ multilevel\\ disk\\ disease\\.\ \(0\)\
\-\ epidural\\ lipomatosis\ \(4\)\
\-\ \\â\\€\\¢\\ epidural\\ lipomatosis\ \(1\)\
\-\ \\â\\€\\¢\\ epidural\\ spread\\ of\\ liposarcoma\ \(1\)\
\-\ \\â\\€\\¢\\ extradural\\ lipoma\ \(1\)\
\-\ 76\\ y\\.o\\.\\ man\\ presents\\ with\\ back\\ pain\\ and\\ hyperreflexia\\ in\\ the\\ lower\\ extremities\\.\\ \\ mri\\ of\\ brain\\ showed\\ no\\ focal\\ abnormalities\\.\ \(0\)\
\-\ the\\ cause\\ for\\ this\\ specific\\ case\\ of\\ epidural\\ lipomatosis\\ is\\ currently\\ unknown\\.\\ \\ this\\ man\\ is\\ not\\ obease\\ nor\\ does\\ he\\ currently\\ have\\ a\\ diagnosed\\ endocrinopathy\\.\\ \\ additionally\\,\\ he\\ does\\ not\\ take\\ steriods\\ for\\ some\\ underlying\\ condition\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ epidural\\:\\ 0\\.14721497335588835\ \(0\)\
\-\ lipomatosis\\:\\ 0\\.14411765611701788\ \(0\)\
\-\ hyperreflexia\\:\\ 0\\.08854002481368528\ \(0\)\
\-\ currently\\:\\ 0\\.07103859010514806\ \(0\)\
\-\ \\+3\\:\\ 0\\.06164698198577971\ \(0\)\
\-\ obease\\:\\ 0\\.06164698198577971\ \(0\)\
\-\ endocrinopathy\\:\\ 0\\.06164698198577971\ \(0\)\
\-\ dorsal\\:\\ 0\\.060833710563803\ \(0\)\
\-\ t6\\-7\\:\\ 0\\.0539643785685202\ \(0\)\
\-\ steriods\\:\\ 0\\.05039217140931747\ \(0\)\
\-\ extremities\\:\\ 0\\.04687673592924319\ \(0\)\
\-\ sub\\:\\ 0\\.04487848357460229\ \(0\)\
\-\ t9\\:\\ 0\\.04319203562483384\ \(0\)\
\-\ multilevel\\:\\ 0\\.04225824966242459\ \(0\)\
\-\ does\\:\\ 0\\.04077791706830778\ \(0\)\
\-\ extradural\\:\\ 0\\.03942282932600386\ \(0\)\
\-\ t3\\:\\ 0\\.03859917173400118\ \(0\)\
\-\ meds\\:\\ 0\\.03678440812921038\ \(0\)\
\-\ proliferation\\:\\ 0\\.03602766977508288\ \(0\)\
\-\ ventral\\:\\ 0\\.03602766977508288\ \(0\)\
\-\ liposarcoma\\:\\ 0\\.03602766977508288\ \(0\)\
\-\ take\\:\\ 0\\.03429017775201645\ \(0\)\
\-\ 76\\:\\ 0\\.0337519886531624\ \(0\)\
\-\ he\\:\\ 0\\.03334527751095132\ \(0\)\
\-\ conservatively\\:\\ 0\\.03325227561832223\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.03287442695655709\ \(0\)\
\-\ effacement\\:\\ 0\\.032785902370079764\ \(0\)\
\-\ flattening\\:\\ 0\\.032563883500747036\ \(0\)\
\-\ disk\\:\\ 0\\.032348697076504\ \(0\)\
\-\ nor\\:\\ 0\\.0319372250483716\ \(0\)\
\-\ arachnoid\\:\\ 0\\.03002608284557663\ \(0\)\
\-\ spread\\:\\ 0\\.028904805572323625\ \(0\)\
\-\ man\\:\\ 0\\.02826478102223775\ \(0\)\
\-\ lipoma\\:\\ 0\\.027938719289240986\ \(0\)\
\-\ mri\\:\\ 0\\.027458403565239438\ \(0\)\
\-\ lower\\:\\ 0\\.026879189781312762\ \(0\)\
\-\ needed\\:\\ 0\\.026026351210907246\ \(0\)\
\-\ additionally\\:\\ 0\\.02589881563363605\ \(0\)\
\-\ underlying\\:\\ 0\\.02560997782845258\ \(0\)\
\-\ condition\\:\\ 0\\.024991408453894096\ \(0\)\
\-\ specific\\:\\ 0\\.024701501365234333\ \(0\)\
\-\ levels\\:\\ 0\\.024666093659244496\ \(0\)\
\-\ results\\:\\ 0\\.024122674188424103\ \(0\)\
\-\ canal\\:\\ 0\\.023741142830029455\ \(0\)\
\-\ moderate\\:\\ 0\\.023497883276984592\ \(0\)\
\-\ stenosis\\:\\ 0\\.02340879918063893\ \(0\)\
\-\ unknown\\:\\ 0\\.023320835668702845\ \(0\)\
\-\ cord\\:\\ 0\\.022707509931506303\ \(0\)\
\-\ diagnosed\\:\\ 0\\.02197339270486018\ \(0\)\
\-\ abnormalities\\:\\ 0\\.021949402948938577\ \(0\)\
\-\ complete\\:\\ 0\\.021030600936965415\ \(0\)\
\-\ being\\:\\ 0\\.02082369214545845\ \(0\)\
\-\ cause\\:\\ 0\\.020218619766097665\ \(0\)\
\-\ space\\:\\ 0\\.019766132916619824\ \(0\)\
\-\ back\\:\\ 0\\.019713750596835503\ \(0\)\
\-\ spine\\:\\ 0\\.019679045776261173\ \(0\)\
\-\ central\\:\\ 0\\.019661757740279433\ \(0\)\
\-\ showed\\:\\ 0\\.019593029845620256\ \(0\)\
\-\ fat\\:\\ 0\\.01817421204812331\ \(0\)\
\-\ some\\:\\ 0\\.018146351425641673\ \(0\)\
\-\ brain\\:\\ 0\\.0179814791839354\ \(0\)\
\-\ treated\\:\\ 0\\.017887068783803212\ \(0\)\
\-\ not\\:\\ 0\\.01727019121317392\ \(0\)\
\-\ y\\.o\\:\\ 0\\.017247408619487415\ \(0\)\
\-\ level\\:\\ 0\\.017223000193335187\ \(0\)\
\-\ focal\\:\\ 0\\.017066388840128684\ \(0\)\
\-\ mild\\:\\ 0\\.01573603813937858\ \(0\)\
\-\ is\\:\\ 0\\.015728413381390926\ \(0\)\
\-\ pain\\:\\ 0\\.014595918427003283\ \(0\)\
\-\ associated\\:\\ 0\\.014101136796557357\ \(0\)\
\-\ this\\:\\ 0\\.013442478507889972\ \(0\)\
\-\ case\\:\\ 0\\.013073457572498396\ \(0\)\
\-\ demonstrates\\:\\ 0\\.013053295116455846\ \(0\)\
\-\ have\\:\\ 0\\.012940126422133508\ \(0\)\
\-\ \\-\\:\\ 0\\.012809289921037506\ \(0\)\
\-\ presents\\:\\ 0\\.012207302765789692\ \(0\)\
\-\ also\\:\\ 0\\.011780556599091968\ \(0\)\
\-\ which\\:\\ 0\\.011154857253444396\ \(0\)\
\-\ for\\:\\ 0\\.010197316764233778\ \(0\)\
\-\ disease\\:\\ 0\\.009767395393116812\ \(0\)\
\-\ as\\:\\ 0\\.009039003537721173\ \(0\)\
\-\ there\\:\\ 0\\.008893115779475446\ \(0\)\
\-\ from\\:\\ 0\\.008856193798281205\ \(0\)\
\-\ at\\:\\ 0\\.008096245823997433\ \(0\)\
\-\ the\\:\\ 0\\.007734225717685359\ \(0\)\
\-\ no\\:\\ 0\\.00601709196296365\ \(0\)\
\-\ patient\\:\\ 0\\.005990153363051664\ \(0\)\
\-\ in\\:\\ 0\\.00589366755440916\ \(0\)\
\-\ of\\:\\ 0\\.005702983255845588\ \(0\)\
\-\ a\\:\\ 0\\.0027734251875426662\ \(0\)\
\-\ with\\:\\ 0\\.002454633064822862\ \(0\)\
\-\ \\.\\:\\ 0\\.00223423653759522\ \(0\)\
\-\ \\,\\:\\ 0\\.001893077381239772\ \(0\)\
\-\ and\\:\\ 0\\.0012588042358896395\ \(0\)\
